These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 18564199)

  • 1. The impact of analytic method on interpretation of outcomes in longitudinal clinical trials.
    Prakash A; Risser RC; Mallinckrodt CH
    Int J Clin Pract; 2008 Aug; 62(8):1147-58. PubMed ID: 18564199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder.
    Stein DJ; Lopez AG
    Adv Ther; 2011 Nov; 28(11):1021-37. PubMed ID: 22057726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials.
    Mallinckrodt CH; Raskin J; Wohlreich MM; Watkin JG; Detke MJ
    BMC Psychiatry; 2004 Sep; 4():26. PubMed ID: 15355546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study.
    Pollack MH; Roy-Byrne PP; Van Ameringen M; Snyder H; Brown C; Ondrasik J; Rickels K
    J Clin Psychiatry; 2005 Nov; 66(11):1401-8. PubMed ID: 16420077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods.
    Girardi P; Pompili M; Innamorati M; Mancini M; Serafini G; Mazzarini L; Del Casale A; Tatarelli R; Baldessarini RJ
    Hum Psychopharmacol; 2009 Apr; 24(3):177-90. PubMed ID: 19229839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical choices can affect inferences about treatment efficacy: a case study from obsessive-compulsive disorder research.
    Simpson HB; Petkova E; Cheng J; Huppert J; Foa E; Liebowitz MR
    J Psychiatr Res; 2008 Jul; 42(8):631-8. PubMed ID: 17892885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
    Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
    Bauer M; Demyttenaere K; El-Khalili N; Thase ME; Papakostas GI; Szamosi J; Earley WR; Eriksson H
    Int Clin Psychopharmacol; 2014 Jan; 29(1):16-25. PubMed ID: 24108148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
    Mallick R; Chen J; Entsuah AR; Schatzberg AF
    J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials.
    Dunner DL; Lipschitz A; Pitts CD; Davies JT
    Clin Ther; 2005 Dec; 27(12):1901-11. PubMed ID: 16507376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials.
    Kornstein SG; Li D; Mao Y; Larsson S; Andersen HF; Papakostas GI
    CNS Spectr; 2009 Jun; 14(6):326-33. PubMed ID: 19668123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.
    Schmidt ME; Fava M; Robinson JM; Judge R
    J Clin Psychiatry; 2000 Nov; 61(11):851-7. PubMed ID: 11105738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group.
    Berk M; du Plessis AD; Birkett M; Richardt D
    Int Clin Psychopharmacol; 1997 May; 12(3):137-40. PubMed ID: 9248869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining efficacy and completion rates with no data imputation: a composite approach with greater sensitivity for the statistical evaluation of active comparisons in antipsychotic trials.
    Rabinowitz J; Werbeloff N; Caers I; Mandel FS; Jaeger J; Stauffer V; Menard F; Kinon BJ; Kapur S
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):357-68. PubMed ID: 24370073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.
    Bech P; Kajdasz DK; Porsdal V
    Psychopharmacology (Berl); 2006 Oct; 188(3):273-80. PubMed ID: 16960699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response.
    Wade AG; Crawford GM; Nemeroff CB; Schatzberg AF; Schlaepfer T; McConnachie A; Haazen L; Buntinx E
    Psychol Med; 2011 Oct; 41(10):2089-97. PubMed ID: 21349239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.
    Kornstein SG; Wohlreich MM; Mallinckrodt CH; Watkin JG; Stewart DE
    J Clin Psychiatry; 2006 May; 67(5):761-70. PubMed ID: 16841626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
    Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W;
    Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.